一心堂药业集团为控股子公司四川本草堂药业提供重大担保进展公告详解

公告要点与投资者关注事项

• 担保事项：一心堂药业集团股份有限公司（股票代码：002727，简称“一心堂”）决定为其控股子公司四川本草堂药业有限公司（以下简称“四川本草堂”）向银行申请授信额度提供连带责任保证担保，担保金额高达人民币8,000万元。
• 风险提示：四川本草堂最近一期（2024年12月31日）经审计的资产负债率超过70%，公司特别提醒投资者关注担保风险。这一高负债水平意味着一旦四川本草堂出现偿债困难，作为担保方的一心堂将承担较大财务风险。
• 担保协议详情：最新签署的《最高额保证合同》明确，一心堂为四川本草堂向华夏银行成都分行申请的最高8,000万元授信额度提供连带责任保证，担保范围包括主债权本金、利息、逾期利息、罚息、复利、违约金、损害赔偿金、汇率损失以及实现债权的所有合理费用。保证期间为主合同项下每笔债务履行期届满之日起三年。
• 授信额度与对外担保情况：本次担保属于股东大会已审议通过的14.08亿元综合授信额度范围内，无需再次履行审议程序。公告披露后，公司及控股子公司担保额度总计13.5亿元，当前对外担保余额为8.84亿元，占2024年度净资产的11.55%，公司无逾期担保，也未对合并报表外单位提供担保。
• 反担保措施：四川本草堂的其他参股股东将按出资比例向一心堂提供反担保，以分担风险。
• 被担保企业基本情况：四川本草堂药业有限公司注册资本1.25亿元，主要从事药品批发、互联网信息服务、医疗器械经营、食品销售等业务。一心堂持有其56%股权，为第一大股东。截止2024年12月31日，四川本草堂总资产13.92亿元，负债11.62亿元，净资产2.31亿元，信用状况良好，不属于失信被执行人。
• 担保的必要性与合理性：公司认为本次担保有助于四川本草堂满足日常经营资金需求，支持其稳健发展，对提升集团整体效益具有积极作用。公司认为风险可控，不会损害公司及股东利益。
• 关键时间节点：此次相关议案已于2025年12月10日股东大会审议通过，公告发布时间为2026年4月23日。

投资者须知的潜在影响与风险提示

本次重大担保事项对一心堂药业集团的财务安全、信用水平及未来现金流可能产生直接影响，尤其考虑到四川本草堂资产负债率较高，未来若经营出现波动，或将导致一心堂需承担较高的担保责任，进而影响公司盈利能力、资本结构甚至股价表现。同时，当前总担保余额已占公司净资产11.55%，需持续关注担保风险累积情况。

对于持有一心堂股票的投资者而言，此次担保进展，以及四川本草堂的财务健康状况和偿债能力，是影响公司未来业绩和股价波动的重要因素，具备明显的价格敏感性，建议密切关注后续进展及四川本草堂的经营状况变动。

免责声明

本文信息来源于一心堂药业集团股份有限公司公告，仅供投资者参考，不构成任何投资建议。投资者据此操作，风险自担。请持续关注公司后续公告及相关财务信息披露。

English Version

Detailed Analysis of Yixintang Pharmaceutical Group’s Major Guarantee for Subsidiary Sichuan BenCaoTang

Key Points and Investor Highlights

• Guarantee Details: Yixintang Pharmaceutical Group Co., Ltd. (stock code: 002727, “Yixintang”) has resolved to provide a joint liability guarantee for its majority-owned subsidiary, Sichuan BenCaoTang Pharmaceutical Co., Ltd. (“BenCaoTang”), supporting its bank credit line application up to RMB 80 million.
• Risk Alert: BenCaoTang’s latest audited financials (as of December 31, 2024) show an asset-liability ratio exceeding 70%. The company specifically reminds investors of the associated guarantee risks. Such a high leverage ratio means that if BenCaoTang faces repayment difficulties, Yixintang, as the guarantor, could face significant financial exposure.
• Contract Details: The newly signed “Maximum Guarantee Contract” stipulates that Yixintang provides a joint liability guarantee for BenCaoTang’s up to RMB 80 million credit line with Huaxia Bank Chengdu Branch. The guarantee covers principal, interest, overdue interest, penalty interest, compound interest, liquidated damages, compensation, exchange losses, and all reasonable costs related to debt recovery. The guarantee period is three years after each debt maturity under the main contract.
• Credit and Guarantee Situation: This guarantee is within the RMB 1.408 billion total credit line previously approved by shareholders, requiring no further approval. The company and subsidiaries’ total guarantee limit is now RMB 1.35 billion, with current guarantee balances at RMB 884 million, representing 11.55% of 2024 audited net assets. There are no overdue guarantees or guarantees for non-consolidated entities.
• Counter-Guarantee Measure: Other BenCaoTang shareholders will provide counter-guarantees to Yixintang proportionate to their equity interests to share the risk.
• Subsidiary Profile: BenCaoTang has RMB 125 million registered capital, mainly engaged in pharmaceutical wholesale, internet medical services, medical device operations, and food sales. Yixintang holds a 56% controlling stake. As of December 31, 2024, BenCaoTang had total assets of RMB 1.392 billion, liabilities of RMB 1.162 billion, and net assets of RMB 231 million. The company has a good credit record and is not a defaulter.
• Necessity and Rationale: The guarantee is deemed necessary for BenCaoTang’s daily operations and business growth. Yixintang believes the risk is controllable, and the arrangement will not harm shareholder interests.
• Timeline: The relevant proposal was approved at the December 10, 2025, shareholders’ meeting. The announcement was made on April 23, 2026.

Potential Impact and Risks for Investors

This major guarantee could directly affect Yixintang’s financial security, credit standing, and future cash flows—especially as BenCaoTang’s high leverage exposes Yixintang to significant contingent liabilities. With guarantee balances already at 11.55% of net assets, investors should closely monitor potential cumulative risk.

For shareholders, this development and BenCaoTang’s financial health are highly price-sensitive and could influence company performance and share price volatility. Investors are strongly advised to follow future disclosures and monitor any changes in BenCaoTang’s operations and repayment ability.

Disclaimer

The information above is based on Yixintang Pharmaceutical Group’s official announcement and is provided for reference only. It does not constitute investment advice. Investors should make decisions at their own risk and pay close attention to further company disclosures and financial reports.

View 一心堂 Historical chart here